EA199800015A1 - Способ ингибирования меланомы - Google Patents

Способ ингибирования меланомы

Info

Publication number
EA199800015A1
EA199800015A1 EA199800015A EA199800015A EA199800015A1 EA 199800015 A1 EA199800015 A1 EA 199800015A1 EA 199800015 A EA199800015 A EA 199800015A EA 199800015 A EA199800015 A EA 199800015A EA 199800015 A1 EA199800015 A1 EA 199800015A1
Authority
EA
Eurasian Patent Office
Prior art keywords
melanoma
inhibiting
inhibiting melanoma
hexamethyleneimino
pyrrolidino
Prior art date
Application number
EA199800015A
Other languages
English (en)
Other versions
EA000680B1 (ru
Inventor
Роберт А. Свифт
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA199800015A1 publication Critical patent/EA199800015A1/ru
Publication of EA000680B1 publication Critical patent/EA000680B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Способ ингибирования меланомы, включающий введение человеку, который в этом нуждается, эффективного количества соединения формулы Iв котором Rи Rнезависимо представляют водород, -CH, (а) или (b), где Ar представляет необязательно замещенный фенил; Rвыбирают из группы, состоящей из пирролидино, гексаметиленимино и пиперидино; или его фармацевтически приемлемой соли или сольвата отдельно или в сочетании с одним или более агентов, ингибирующих меланому.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199800015A 1995-06-06 1996-06-06 Способ ингибирования меланомы EA000680B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/466,673 US5843974A (en) 1995-06-06 1995-06-06 Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
PCT/US1996/009839 WO1996039135A1 (en) 1995-06-06 1996-06-06 Methods of inhibiting melanoma

Publications (2)

Publication Number Publication Date
EA199800015A1 true EA199800015A1 (ru) 1998-06-25
EA000680B1 EA000680B1 (ru) 2000-02-28

Family

ID=23852667

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199800015A EA000680B1 (ru) 1995-06-06 1996-06-06 Способ ингибирования меланомы

Country Status (16)

Country Link
US (1) US5843974A (ru)
EP (1) EP0747053A3 (ru)
JP (1) JPH11507371A (ru)
KR (1) KR19990022364A (ru)
CN (1) CN1192141A (ru)
AU (1) AU702716B2 (ru)
CA (1) CA2223157A1 (ru)
CZ (1) CZ383197A3 (ru)
EA (1) EA000680B1 (ru)
HU (1) HUP9901093A3 (ru)
IL (1) IL118574A0 (ru)
MX (1) MX9709466A (ru)
NO (1) NO975580D0 (ru)
PL (1) PL323924A1 (ru)
WO (1) WO1996039135A1 (ru)
ZA (1) ZA964682B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048847A (en) * 1997-09-30 2000-04-11 Dabur Research Foundation Use of betulinic acid and its derivatives for inhibiting cancer growth and a method of monitoring this
US6228850B1 (en) * 1997-09-30 2001-05-08 Dabur Research Foundation Antiangiogenic activity of betulinic acid and its derivatives
US6670345B1 (en) 1997-09-30 2003-12-30 Dabur Research Foundation Betulinic acid derivatives for inhabiting cancer growth and process for the manufacture of betulinic acid
DK1175433T3 (da) 1999-05-04 2005-09-19 Strakan Int Ltd Androgenglycosider og androgen aktivitet deraf
JP5650367B2 (ja) * 2004-02-27 2015-01-07 アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物
US20050267060A1 (en) * 2004-03-19 2005-12-01 The Penn State Research Foundation Combinatorial methods and compositions for treatment of melanoma
CA3211094A1 (en) 2012-08-13 2014-02-20 The Rockefeller University Treatment and diagnosis of melanoma
EP3091970B1 (en) 2014-01-10 2020-10-28 Rgenix, Inc. Lxr agonists and uses thereof
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
US11214536B2 (en) 2017-11-21 2022-01-04 Inspirna, Inc. Polymorphs and uses thereof
CN114728875A (zh) 2019-12-13 2022-07-08 因思博纳公司 金属盐及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5457113A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
CN1058390C (zh) * 1993-10-15 2000-11-15 伊莱利利公司 苯并噻吩类化合物的用途
KR950010891A (ko) * 1993-10-15 1995-05-15 피터 지. 스트링거 내성 종양을 치료하는 방법
US5476862A (en) * 1993-12-21 1995-12-19 Eli Lilly And Company Methods of increasing thrombomodulin expression
US5622975A (en) * 1995-06-01 1997-04-22 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell migration
US5726168A (en) * 1995-10-12 1998-03-10 Eli Lilly And Company Lipophilic benzothiophenes
US5780497A (en) * 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents

Also Published As

Publication number Publication date
PL323924A1 (en) 1998-04-27
NO975580L (no) 1997-12-03
EP0747053A3 (en) 1997-01-29
HUP9901093A3 (en) 2000-02-28
US5843974A (en) 1998-12-01
AU6109096A (en) 1996-12-24
AU702716B2 (en) 1999-03-04
EA000680B1 (ru) 2000-02-28
ZA964682B (en) 1997-12-05
IL118574A0 (en) 1996-10-16
HUP9901093A2 (hu) 1999-10-28
JPH11507371A (ja) 1999-06-29
CN1192141A (zh) 1998-09-02
CA2223157A1 (en) 1996-12-12
EP0747053A2 (en) 1996-12-11
MX9709466A (es) 1998-02-28
NO975580D0 (no) 1997-12-03
WO1996039135A1 (en) 1996-12-12
KR19990022364A (ko) 1999-03-25
CZ383197A3 (cs) 1998-07-15

Similar Documents

Publication Publication Date Title
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
DE69430465T2 (de) Hemmung uteriner Fibrose
EA199700450A1 (ru) Способы подавления миграции сосудистых гладкомышечных клеток
MX9701329A (es) Metodos para la inhibicion de la replicacion viral.
ATE168887T1 (de) Hemmung von dysfunctionalen uterusblutungen
DK0652004T3 (da) Fremgangsmåder til behandling af resistente neoplasmer
EA199800015A1 (ru) Способ ингибирования меланомы
DK0652002T3 (da) Anvendelse af 2-phenyl-3-aroylebenzothiophener til fremstilling af et medikament til hæmning af brusknedbrydning
ATE207748T1 (de) Hemmung einer fehlentwicklung der ovarien, verspüteter pubertät oder sexuellem infantilismus
EA199800019A1 (ru) Способ повышения плотности кальциевых каналов
KR950016734A (ko) 성적 조숙증의 억제방법
EA199700136A1 (ru) Способы ингибирования экзогенных эстрогенов
EA199800366A1 (ru) Способы ингибирования ингибитора 1 активатора плазминогена
EA199700200A1 (ru) Способы ингибирования рака яичника
EA200000243A1 (ru) Способы снижения количества тромбоцитов
KR950016728A (ko) 여성에서 다모증 및 탈모증을 억제하는 방법
EA199800678A1 (ru) Способ ингибирования мышечно-апоневротических фиброматозов (десмоидных опухолей)
MX9701333A (es) Metodos para inhibir el daño neuronal.
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
MX9701327A (es) Metodos para inhibir el cancer endometrial.
EA199800677A1 (ru) Способ ингибирования опухоли толстой кишки
EA199800033A1 (ru) Антагонисты канала кальция
ATE200623T1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung der primären endometriumhyperplasie
MX9705940A (es) Metodos y composiciones para inhibir los efectos de la interleucina 6.
MX9701328A (es) Metodos de reduccion de la cicatrizacion en la curacion de heridas.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU